

5/1/02

RECD S.E.C.  
MAY 16 2002  
1086

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549



Form 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2002

Taro Pharmaceutical Industries Ltd.  
(Translation of registrant's name into English)

14 Hakitor Street, Haifa Bay 26110, Israel  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  No

PROCESSED  
MAY 23 2002  
THOMSON  
FINANCIAL

*Wky*

The following is included in this Report on Form 6-K:

1. Report of Share Issuance presented to the Israel Registrar of Companies in May, 2002.
2. Press Release dated May 8, 2002.

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 12, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 49  
For Cash Consideration: 49

### Additional Holders of Ordinary Shares

		Par value	No. of shares	Price per share
I.D. number:	Canadian Resident			
Shareholder:	Sikander Remtulla	<b>0.0001</b>	<b>24</b>	<b>11.39</b>
			<b>25</b>	<b>11.63</b>

Address: 62 Lappin Avenue  
Toronto, Ontario M6I 1Y4  
Canada

Cash allocation  
Amount regarded as paid 24 – 11.39NIS; 25 – 11.63NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 13, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 12, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 25  
For Cash Consideration: 25

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Canadian Resident VN889386			
Shareholder: Ramdial Singh	<b>0.0001</b>	<b>25</b>	<b>11.60</b>

Address: 1207-1375 Midland Ave.  
Scarborough, ONT M1P 3B7  
CANADA

Cash allocation  
Amount regarded as paid 25 – 11.60NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 13, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 11, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 2,500  
For Cash Consideration: 2,500

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: USA Resident Shareholder: Robert Henson	<b>0.0001</b>	<b>2,500</b>	<b>28.85</b>

Address: 1449 N. Los Alamos  
Mesa, AZ 85213-4220  
USA

Cash allocation  
Amount regarded as paid 2,500 – 28.85NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 13, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 11, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 49  
For Cash Consideration: 49

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Canadian Resident 4658141			
Shareholder: Jason Joseph	<b>0.0001</b>	<b>24</b>	<b>11.38</b>
		<b>25</b>	<b>11.61</b>
Address: 81 Faywood Drive Brampton, ONT L6Y 4M1 CANADA			

Cash allocation  
Amount regarded as paid 24 – 11.38NIS; 25 – 11.61NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 12, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 11, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 49  
For Cash Consideration: 49

### Additional Holders of Ordinary Shares

		Par value	No. of shares	Price per share
I.D. number:	Canadian Resident VF961034			
Shareholder:	Hasan Qazi	<b>0.0001</b>	<b>24</b>	<b>11.38</b>
			<b>25</b>	<b>11.61</b>
Address:	66 Coppard Ave. Markham, Ontario L3S 2R2 CANADA			

Cash allocation  
Amount regarded as paid 24 – 11.38NIS; 25 – 11.61NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 12, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 8, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 49  
For Cash Consideration: 49

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Canadian Passport VK 297567			
Shareholder: Patricia Mohabir	<b>0.0001</b>	<b>24</b>	<b>11.38</b>
		<b>25</b>	<b>11.59</b>
Address: 33 Livingston Drive Caledon, ONT L7C 1A1 CANADA			

Cash allocation  
Amount regarded as paid 24 – 11.38NIS; 25 – 11.59NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 10, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 8, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 49  
For Cash Consideration: 49

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Canadian Resident 61-05-028675			
Shareholder: Frank Calver	<b>0.0001</b>	<b>24</b>	<b>11.38</b>
		<b>25</b>	<b>11.61</b>

Address: 41 Kenwell Cres  
Barrie, Ontario L4N 0A3  
CANADA

Cash allocation  
Amount regarded as paid 24 – 11.38NIS; 25 – 11.61NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 10, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 27, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 25  
For Cash Consideration: 25

### Additional Holders of Ordinary Shares

		Par value	No. of shares	Price per share
I.D. number:	Driver's License #0508-70606-423			
Shareholder:	Shen Gao	<b>0.0001</b>	<b>25</b>	<b>11.60</b>

Address: 5 Ridgefield Court  
Brampton, ONT L6P 1B6  
CANADA

Cash allocation  
Amount regarded as paid 25 – 11.60NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 31, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 12, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 49  
For Cash Consideration: 49

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Canadian Resident SO484-29604-81108			
Shareholder: Godfredo Santiago	<b>0.0001</b>	<b>24</b>	<b>11.67</b>
		<b>25</b>	<b>11.90</b>
Address: 516 Ashprior Avenue Mississauga, ONT L5R 3N1 CANADA			

Cash allocation  
Amount regarded as paid 24 – 11.67NIS; 25 – 11.90NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: April 4, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: April 1, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 1,250  
For Cash Consideration: 1,250

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Canadian Resident			
Shareholder: Craig Fields	<b>0.0001</b>	<b>1,250</b>	<b>12.98</b>

Address: 91 Kingsway Crescent  
Etobicoke, ONT M8X 2R8  
CANADA

Cash allocation  
Amount regarded as paid 1,250 – 12.98NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: April 4, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 20, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 1,250  
For Cash Consideration: 1,250

### Additional Holders of Ordinary Shares

		Par value	No. of shares	Price per share
I.D. number:	Israeli ID # 0998540-9			
Shareholder:	Zahava Rafalowicz	<b>0.0001</b>	<b>1,250</b>	<b>26.58</b>

Address: Hooverman St #24  
Tel-Aviv 64075  
ISRAEL

Cash allocation  
Amount regarded as paid 1,250 – 26.58NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 21, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 26, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 1,000  
For Cash Consideration: 1,000

### Additional Holders of Ordinary Shares

		Par value	No. of shares	Price per share
I.D. number:	US Passport # 093241410			
Shareholder:	Walter Jenkins	<b>0.0001</b>	<b>1,000</b>	<b>14.14</b>
Address:	56 Duke Drive Carmel, NY 10512 U.S.A.			

Cash allocation  
Amount regarded as paid 1,000 – 14.14NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 31, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: March 25, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 25  
For Cash Consideration: 25

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Canadian ID 3632306			
Shareholder: Nick Spatari	<b>0.0001</b>	<b>25</b>	<b>11.57</b>

Address: 43 Coral Gable Dr.  
Toronto, ONT M9M 1N8  
CANADA

Cash allocation  
Amount regarded as paid 25 – 11.57NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 31, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: February 27, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 750  
For Cash Consideration: 750

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: Israeli ID 07698315-4			
Shareholder: Sabar Sasson	<b>0.0001</b>	<b>250</b>	<b>11.05</b>
		<b>250</b>	<b>11.33</b>
		<b>250</b>	<b>11.51</b>

Address: HaNassi HaRishon St. #42  
Rehovot 76302  
ISRAEL

Cash allocation  
Amount regarded as paid 250 – 11.05NIS; 250 – 11.33NIS;  
for each share: 250 – 11.51NIS

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: March 31, 2002

## Report of Share Issuance

Company: Taro Pharmaceutical Industries Limited  
Date of Issuance: February 22, 2002  
No. of Company: 52-002290-6

Name of Shares: Ordinary  
Symbol of Shares: Ord.  
Par Value: NIS 0.0001  
No. of Shares Issued: 4,000  
For Cash Consideration: 4,000

### Additional Holders of Ordinary Shares

	Par value	No. of shares	Price per share
I.D. number: USA Resident			
Shareholder: Edmund Sonnenblick	<b>0.0001</b>	<b>4,000</b>	<b>12.36</b>

Address: U.S.A.

Cash allocation  
Amount regarded as paid 4,000 – 12.36NIS  
for each share:

Reported by: Kevin Connelly  
I.D. number  
Title: Chief Financial Officer  
Date: February 24, 2002

## Taro Purchases Assets of Thames Pharmacal

### Acquires ANDAs and OTC Operations

HAWTHORNE, N.Y.--May 8, 2002--Taro Pharmaceutical Industries Ltd. (NASDAQ/NMS:TARO) today announced that it has purchased substantially all the assets of Thames Pharmacal Company, Inc. ("Thames"), a privately-held New York manufacturer of prescription and over-the-counter pharmaceuticals.

Thames had sales of approximately \$9 million in 2001. The transaction was effected through a cash consideration of less than one times 2001 sales. The acquired assets include the rights to all of Thames' generic prescription and over-the-counter ("OTC") products, as well as Thames' laboratories and manufacturing operations.

Thames manufactures and markets a number of dermatologic prescription and OTC generic products, which complement Taro's broad line of topical corticosteroids and antifungal products. "We expect to achieve considerable leverage through the integration of Thames' product portfolio into Taro's sales and marketing programs," said Robert Mauro, Group Vice President of Sales for North America, Taro Pharmaceuticals U.S.A., Inc. "We also have the opportunity to optimize the manufacturing of Thames' products through the integration of our two companies."

Advest, Inc. served as financial advisors to Thames in the transaction.

#### About Thames

Thames, established in 1978, employs approximately 60 people in its leased facilities, which include laboratories, manufacturing and warehousing operations in Ronkonkoma, New York.

Thames' facilities and operations have been regularly inspected and its Abbreviated New Drug Applications have been approved by the United States Food and Drug Administration. Thames sells principally to distributors, wholesalers, and retail drug chains. Its products are available under the Thames label or in private label packaging. In addition, Thames manufactures products for other pharmaceutical companies, including custom formulations.

#### Contact Information

Effective immediately, Thames products will be sold by a wholly owned subsidiary of Taro called Thames Pharmaceuticals, Inc. Customers and suppliers should contact Thames as they have in the past.

Taro is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at [www.taro.com](http://www.taro.com).

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that are not describing historical facts, such as comments describing what the company or its officers "expect," or comments describing an "opportunity," or similar statements; comments concerning Taro's expectations regarding the acquisition of the assets of Thames Pharmacal, including comments concerning the sales potential of Thames' products, the use of Thames' product portfolio to leverage

Taro's marketing programs, the complementary nature of the product lines of Thames and Taro, and the integration of the operations of Thames and Taro. Although Taro believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors that could cause actual results to differ include the viability of Thames' operations following Taro's acquisition of Thames assets, difficulties in integrating the operations of Thames and Taro, non-acceptance of Thames products in the marketplace, industry and market conditions, slower than anticipated regulatory approval of new generic products, other regulatory actions, slower than anticipated penetration of new markets, changes in the Company's financial position, the situation in the Middle East and other risks detailed from time to time in the Company's SEC reports, including its Prospectus dated October 1, 2001.

--30--

CONTACT: Taro Pharmaceutical  
Kevin Connelly, 914/345-9001, ext. 338  
Daniel Saks, 914/345-9001, ext. 208

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Taro Pharmaceutical Industries Ltd.

Date: May 15, 2002

By: Kevin Connelly  
Kevin Connelly  
Vice President and Chief  
Financial Officer